Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2003

View Archived Issues

Pfizer presents new CCR1 antagonists for arthritis and other disorders

Novel factor Xa inhibitors developed at BMS

Vertex describes new protein kinase inhibitors

Cytovia scientists design caspase activators and apoptosis inducers

Arizona State U. researchers design new combretastatin A3 prodrugs

Pyrimidine-based tyrosine kinase inhibitors covered by Merck patent

Dual-target antibacterial compounds discovered at Microbiotix

Novel antibacterial isoxazolones prepared and tested by Pharmacia scientists

AnorMED files orphan drug application for AMD-3100

Second phase III study planned for LAX-101

Antex files initial IND for Tracvax

Applied Genetic Technologies' A1AD treatment granted orphan drug status

Positive phase III results obtained for Metformin GR in type 2 diabetes

NP-1 demonstrates efficacy in phase II neuropathy trial

Enrollment completed in phase III trial of MBI-226

Northfield submits response to FDA regarding PolyHeme phase III trial

Goal attainment in donepezil-treated AD patients and correlation with standard measures of efficacy

New phase I trial for VNP-40101M in solid tumors

Improvement of hyperandrogenic alopecia in women after 1-year treatment with flutamide

Grant supports study of HE-2200 for treatment of traumatic shock

AOD-9604 progresses in clinic

SBIR grant supports MitoKor efforts in glaucoma

2C3 antibody inhibits tumor growth by 75%

Preclinical profile of SU-11248 and PK/PD data published

FDA aims to improve and streamline the drug development and review process

Safety of DEAE-rebeccamycin in patients with advanced hepatobiliary cancer

Cialis now available for prescription in several markets

Abbott Japan begins operations

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...